Initial Statement of Beneficial Ownership (3)
February 16 2021 - 5:34PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Decheng Capital Global Life Sciences Fund IV, L.P. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/5/2021
|
3. Issuer Name and Ticker or Trading Symbol
Equillium, Inc. [EQ]
|
(Last)
(First)
(Middle)
UGLAND HOUSE, P.O. BOX 309 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
GRAND CAYMAN, E9 KY1-1104
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock (1) | 3285710 | I | See Footnote (2) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Warrant (right to buy) (1) | 2/5/2021 | 2/5/2026 | Common Stock | 985713 | $14.00 | I | See Footnote (2) |
Explanation of Responses: |
(1) | The reportable securities are included within 3,285,710 units representing (i) 3,285,710 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), and (ii) warrants to purchase an additional 985,713 shares of Common Stock for $7.00 per unit (each unit consisting of one share of Common Stock and a warrant to purchase 0.3 of a share of Common Stock). |
(2) | The reportable securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (the "Fund"). Decheng Capital Management IV (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Decheng Capital Global Life Sciences Fund IV, L.P. UGLAND HOUSE, P.O. BOX 309 GRAND CAYMAN, E9 KY1-1104 |
| X |
|
|
Decheng Capital Management IV (Cayman), LLC UGLAND HOUSE, P.O .BOX 309 GRAND CAYMAN, E9 KY1-1104 |
| X |
|
|
Cui Xiangmin UGLAND HOUSE, P.O .BOX 309 GRAND CAYMAN, E9 KY1-1104 |
| X |
|
|
Signatures
|
/s/ Xiangmin Cui | | 2/15/2021 |
**Signature of Reporting Person | Date |
/s/ Xiangmin Cui | | 2/15/2021 |
**Signature of Reporting Person | Date |
/s/ Xiangmin Cui | | 2/15/2021 |
**Signature of Reporting Person | Date |
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2023 to Apr 2024